All In Biotech

Drug Trial Radar · NCT00628589

Staccato Loxapine in Agitated Patients With Schizophrenia

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation

Last checked: Nov 20, 2026Latest source record: Jul 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 344 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

344

Actual

Start

Feb 2008

Primary completion

May 2008

Study completion May 2008

Sponsor

Lead sponsor
Alexza Pharmaceuticals, Inc.Not stated
Sponsor type
Not stated
First posted
Mar 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients

Conditions

  • Patients With Schizophrenia and Acute Agitation

Interventions

  • Inhaled loxapine 5 mgDrug

    Inhaled loxapine 5 mg

  • Inhaled loxapine 10 mgDrug

    Inhaled loxapine 10 mg

  • Inhaled placeboDrug

    Inhaled placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in PANSS-EC From BaselineTime frame: Baseline and 2 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atlanta Center for Medical Research

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.